RegeneRx Reports Positive Results of Preclinical Dry Eye Study
November 02 2010 - 7:30AM
Business Wire
RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (the
“Company” or “RegeneRx”) today announced the results of its first
non-clinical dry eye study using RGN-259, RegeneRx’s ophthalmic,
preservative-free eye drop for the treatment of Dry Eye Syndrome
(DES). In the study, animals were treated with RGN-259, a vehicle
control and a positive control, doxycycline. Corneal fluorescein
staining was used to measure the surface defects after induction of
DES using an industry accepted dry eye model. In animals treated
with RGN-259, a “dramatic” and statistically significant reduction
in corneal staining (p
Regenerx Biopharm In (AMEX:RGN)
Historical Stock Chart
From Apr 2024 to May 2024
Regenerx Biopharm In (AMEX:RGN)
Historical Stock Chart
From May 2023 to May 2024
